Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

T Cell Activation Pathways: B7, LFA-3, and ICAM-1 Shape Unique T Cell Profiles.

Wingren AG, Parra E, Varga M, Kalland T, Sjogren HO, Hedlund G, Dohlsten M.

Crit Rev Immunol. 2017;37(2-6):463-481. doi: 10.1615/CritRevImmunol.v37.i2-6.130. Review.

PMID:
29773030
2.
3.

Man-made superantigens: Tumor-selective agents for T-cell-based therapy.

Dohlsten M, Kalland T, Gunnarsson P, Antonsson P, Molander A, Olsson J, d'Argy R, Ohlsson L, Soegaard M, Persson R, Brodin TN.

Adv Drug Deliv Rev. 1998 Apr 6;31(1-2):131-142.

PMID:
10837621
4.

Treatment with tumor-reactive Fab-IL-2 and Fab-staphylococcal enterotoxin A fusion proteins leads to sustained T cell activation, and long-term survival of mice with established tumors.

Søgaard M, Ohlsson L, Kristensson K, Rosendahl A, Sjoberg A, Forsberg G, Kalland T, Dohlsten M.

Int J Oncol. 1999 Nov;15(5):873-82.

PMID:
10536168
5.

Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28.

Grosse-Hovest L, Brandl M, Dohlsten M, Kalland T, Wilmanns W, Jung G.

Int J Cancer. 1999 Jan 5;80(1):138-44.

6.
8.

Targeted superantigens for immunotherapy of haematopoietic tumours.

Tötterman TH, Gidlöf C, Ragnarsson L, Högbom E, Lindeberg M, von der Lehr N, Einarsson A, Soegaard M, Kristensson K, Kalland T, Dohlsten M.

Vox Sang. 1998;74 Suppl 2:483-7. Review.

PMID:
9704486
9.

Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens.

Rosendahl A, Kristensson K, Hansson J, Riesbeck K, Kalland T, Dohlsten M.

J Immunol. 1998 Jun 1;160(11):5309-13.

10.

Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth.

Rosendahl A, Kristensson K, Hansson J, Ohlsson L, Kalland T, Dohlsten M.

Int J Cancer. 1998 Apr 13;76(2):274-83.

11.

Efficient selection of scFv antibody phage by adsorption to in situ expressed antigens in tissue sections.

Tordsson J, Abrahmsén L, Kalland T, Ljung C, Ingvar C, Brodin T.

J Immunol Methods. 1997 Dec 15;210(1):11-23.

PMID:
9502581
12.

A mutation of F47 to A in staphylococcus enterotoxin A activates the T-cell receptor Vbeta repertoire in vivo.

Rosendahl A, Hansson J, Antonsson P, Sékaly RP, Kalland T, Dohlsten M.

Infect Immun. 1997 Dec;65(12):5118-24.

13.

Superantigen-induced lysis of melanoma cells.

Krull F, Holzer U, Ihle J, Bethge W, Fierlbeck G, Kalland T, Dohlsten M, Niethammer D, Dannecker GE.

Melanoma Res. 1997 Jun;7(3):214-22.

PMID:
9195560
14.

Staphylococcal enterotoxins A, D, and E. Structure and function, including mechanism of T-cell superantigenicity.

Svensson LA, Schad EM, Sundström M, Antonsson P, Kalland T, Dohlsten M.

Prep Biochem Biotechnol. 1997 May-Aug;27(2-3):111-41. Review. No abstract available.

PMID:
9292923
15.

Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer.

Giantonio BJ, Alpaugh RK, Schultz J, McAleer C, Newton DW, Shannon B, Guedez Y, Kotb M, Vitek L, Persson R, Gunnarsson PO, Kalland T, Dohlsten M, Persson B, Weiner LM.

J Clin Oncol. 1997 May;15(5):1994-2007.

PMID:
9164211
16.

Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses.

Litton MJ, Dohlsten M, Hansson J, Rosendahl A, Ohlsson L, Kalland T, Andersson J, Andersson U.

Am J Pathol. 1997 May;150(5):1607-18.

17.

Functional characterization of the interaction between the superantigen staphylococcal enterotoxin A and the TCR.

Antonsson P, Wingren AG, Hansson J, Kalland T, Varga M, Dohlsten M.

J Immunol. 1997 May 1;158(9):4245-51.

PMID:
9126986
18.

Molecular characterization and role in T cell activation of staphylococcal enterotoxin A binding to the HLA-DR alpha-chain.

Thibodeau J, Dohlsten M, Cloutier I, Lavoie PM, Bjork P, Michel F, Léveillé C, Mourad W, Kalland T, Sékaly RP.

J Immunol. 1997 Apr 15;158(8):3698-704.

PMID:
9103433
19.

Prevention of superantigen-induced tolerance in vivo by interleukin-2 treatment.

Belfrage H, Dohlsten M, Hedlund G, Kalland T.

Cancer Immunol Immunother. 1997 Apr;44(2):77-82.

PMID:
9177468
20.

Immunomodulation of autoimmunity by linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis.

Lehmann D, Karussis DM, Fluresco D, Mizrachi-Koll R, Ovadia H, Shezen E, Kalland T, Abramsky O.

J Neuroimmunol. 1997 Apr;74(1-2):102-10.

PMID:
9119961
21.

Genetically engineered superantigens as tolerable antitumor agents.

Hansson J, Ohlsson L, Persson R, Andersson G, Ilbäck NG, Litton MJ, Kalland T, Dohlsten M.

Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2489-94.

22.

A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.

Gidlöf C, Dohlsten M, Lando P, Kalland T, Sundström C, Tötterman TH.

Blood. 1997 Mar 15;89(6):2089-97.

PMID:
9058731
24.

The tumour associated cell surface antigen A6H is costimulatory for human CD4+ but not CD8+ T cells.

Labuda T, Parra E, Hedlund G, Kalland T, Dohlsten M.

Immunology. 1997 Feb;90(2):236-43.

25.

Prevention of superantigen-induced down-regulation of T-cell mediated cytotoxic activity by IL-2 in vivo.

Belfrage H, Dohlsten M, Hedlund G, Kalland T.

Immunology. 1997 Feb;90(2):183-8.

26.

The role of B7-1 and LFA-3 in costimulation of CD8+ T cells.

Parra E, Wingren AG, Hedlund G, Kalland T, Dohlsten M.

J Immunol. 1997 Jan 15;158(2):637-42.

PMID:
8992978
27.

T-cell stimulation and cytokine release induced by staphylococcal enterotoxin A (SEA) and the SEAD227A mutant.

Holzer U, Orlikowsky T, Zehrer C, Bethge W, Dohlsten M, Kalland T, Niethammer D, Dannecker GE.

Immunology. 1997 Jan;90(1):74-80.

28.

Immunoregulatory role of IL-10 during superantigen-induced hyporesponsiveness in vivo.

Sundstedt A, Höiden I, Rosendahl A, Kalland T, van Rooijen N, Dohlsten M.

J Immunol. 1997 Jan 1;158(1):180-6.

PMID:
8977189
29.

Superantigen-mediated cellular cytotoxicity is dependent on antigen expression, but independent of the P-glycoprotein multidrug resistance phenotype.

Zehrer C, Beck J, Gekeler V, Ihle J, Holzer U, Dohlsten M, Kalland T, Niethammer D, Dannecker GE.

Br J Haematol. 1996 Dec;95(3):452-6.

PMID:
8943883
30.

Mutations in the MHC class II binding domains of staphylococcal enterotoxin A differentially affect T cell receptor Vbeta specificity.

Newton DW, Dohlsten M, Olsson C, Segrén S, Lundin KE, Lando PA, Kalland T, Kotb M.

J Immunol. 1996 Nov 1;157(9):3988-94.

PMID:
8892632
31.

Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II.

Lando PA, Olsson C, Kalland T, Newton D, Kotb M, Dohlsten M.

J Immunol. 1996 Oct 1;157(7):2857-63.

PMID:
8816390
32.

Immune response during tumor therapy with antibody-superantigen fusion proteins.

Rosendahl A, Hansson J, Sundstedt A, Kalland T, Dohlsten M.

Int J Cancer. 1996 Sep 27;68(1):109-13.

33.

Antibody-targeted superantigens in cancer immunotherapy.

Søgaard M, Hansson J, Litton MJ, Ohlsson L, Rosendahl A, Lando PA, Antonsson P, Kalland T, Dohlsten M.

Immunotechnology. 1996 Sep;2(3):151-62. Review. No abstract available.

PMID:
9373308
34.

Fusion of a signal sequence to the interleukin-1 beta gene directs the protein from cytoplasmic accumulation to extracellular release.

Wingren AG, Björkdahl O, Labuda T, Björk L, Andersson U, Gullberg U, Hedlund G, Sjögren HO, Kalland T, Widegren B, Dohlsten M.

Cell Immunol. 1996 May 1;169(2):226-37.

PMID:
8620550
35.

In vivo anergized CD4+ T cells express perturbed AP-1 and NF-kappa B transcription factors.

Sundstedt A, Sigvardsson M, Leanderson T, Hedlund G, Kalland T, Dohlsten M.

Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):979-84.

36.

Genetically engineered superantigens in experimental tumor therapy.

Antonsson P, Hansson J, Kalland T, Lando PA, Ohlsson L, Schad E, Svensson A, Dohlsten M.

Springer Semin Immunopathol. 1996;17(4):397-410. Review. No abstract available.

PMID:
8966664
37.

Linomide increases plasma corticosterone in normal rats, but does not prevent the inhibitory action of IL-1 on beta-cells in vivo or ex vivo.

Christensen UB, Mauricio D, Reimers JI, Andersen HU, Kalland T, Nerup J, Mandrup-Poulsen T.

Autoimmunity. 1996;23(4):257-68.

PMID:
8915032
38.

Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma.

Litton MJ, Dohlsten M, Lando PA, Kalland T, Ohlsson L, Andersson J, Andersson U.

Eur J Immunol. 1996 Jan;26(1):1-9.

PMID:
8566049
39.
41.

Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo.

Dohlsten M, Hansson J, Ohlsson L, Litton M, Kalland T.

Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9791-5.

42.

Immunotherapy of human colon cancer by antibody-targeted superantigens.

Dohlsten M, Lando PA, Björk P, Abrahmsén L, Ohlsson L, Lind P, Kalland T.

Cancer Immunol Immunother. 1995 Sep;41(3):162-8.

PMID:
7553685
43.

Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells.

Gidlöf C, Dohlsten M, Kalland T, Tötterman TH.

Leukemia. 1995 Sep;9(9):1534-42.

PMID:
7544852
44.

A novel co-stimulatory T cell antigen co-expressed on renal cell carcinoma.

Labuda T, Lando P, Björkdahl O, Kalland T, Vessella R, Hedlund G, Eriksson H, Sjögren HO, Dohlsten M.

Int Immunol. 1995 Sep;7(9):1425-32.

PMID:
7495750
45.

Tumor-reactive superantigens suppress tumor growth in humanized SCID mice.

Lando PA, Dohlsten M, Ohlsson L, Kalland T.

Int J Cancer. 1995 Aug 9;62(4):466-71.

PMID:
7635573
46.

Enhanced and prolonged efficacy of superantigen-induced cytotoxic T lymphocyte activity by interleukin-2 in vivo.

Belfrage H, Dohlsten M, Hedlund G, Kalland T.

Cancer Immunol Immunother. 1995 Aug;41(2):87-94.

PMID:
7656274
47.

Superantigen-staphylococcal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells.

Holzer U, Bethge W, Krull F, Ihle J, Handgretinger R, Reisfeld RA, Dohlsten M, Kalland T, Niethammer D, Dannecker GE.

Cancer Immunol Immunother. 1995 Aug;41(2):129-36.

PMID:
7656271
48.

Purification of estramustine-binding protein and production of monoclonal antibodies to its different components.

Björk P, Donn F, Glad C, Sundblad G, Vestberg M, Kalland T.

Prostate. 1995 Aug;27(2):70-83.

PMID:
7638085
49.

Costimulation of human CD4+ T cells with LFA-3 and B7 induce distinct effects on AP-1 and NF-kappa B transcription factors.

Parra E, Varga M, Sigvardsson M, Hedlund G, Kalland T, Leanderson T, Sjögren HO, Dohlsten M.

J Immunol. 1995 Aug 1;155(3):1132-40.

PMID:
7543515
50.

Crystal structure of the superantigen staphylococcal enterotoxin type A.

Schad EM, Zaitseva I, Zaitsev VN, Dohlsten M, Kalland T, Schlievert PM, Ohlendorf DH, Svensson LA.

EMBO J. 1995 Jul 17;14(14):3292-301.

Supplemental Content

Loading ...
Support Center